---
title: "editorial hypercholesterolemia"
year: 2024
month: 09
journal: "American Family Physician"
volume: "109-110"
issue: "09"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2024-09-editorial-hypercholesterolemia.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# editorial hypercholesterolemia

Editorials


Familial Hypercholesterolemia:​
Screening, Diagnosis, and Treatment
Brian V. Reamy, MD, FAAFP




F    amilial hypercholesterolemia, an autosomal dominant
     genetic disorder, is characterized by markedly increased
low-density lipoprotein (LDL) cholesterol that causes premature
                                                                         do not follow this guidance because of confusion about the
                                                                         guidelines and concerns about treatment effectiveness.7
                                                                            Family physicians are in an ideal position to bring nuanced,
arteriosclerotic cardiovascular disease (ASCVD). Homozygous              family-centered knowledge to these decisions. The National
familial hypercholesterolemia typically presents with pathogno-          Institute for Health and Care Excellence (NICE) provides one
monic physical findings such as xanthomas or a corneal arcus.            such approach.8 NICE advocates reviewing medical records to
In contrast, heterozygous familial hypercholesterolemia is not           identify families with members older than 16 years who have
indicated by clinical findings and is typically not diagnosed            LDL cholesterol greater than 190 mg per dL (4.92 mmol per L)
until after an early-onset ASCVD event (younger than 50                  and a family history of ASCVD clinical events in men younger
years).1                                                                 than 55 years and women younger than 65 years. These family
   The worldwide prevalence of heterozygous familial hypercho-           members are then screened for dyslipidemia and genetically
lesterolemia is estimated to be 1 in 250 to 350, and ASCVD               tested for familial hypercholesterolemia if the screening shows
events can occur with this condition as young as 17 years in             adults with LDL cholesterol greater than 190 mg per dL or
men and by 25 years of age in women.2-4 Screening for and                children with LDL cholesterol greater than 155 mg per dL
diagnosing familial hypercholesterolemia in childhood can lead           (4.01 mmol per L).9 The American Heart Association endorses
to treatment with lifestyle changes and medication, reducing             screening patients between 9 and 11 years of age to permit early
the serious vascular effects of this dyslipidemia.                       identification of familial hypercholesterolemia and secondary
   In 2023, the U.S. Preventive Services Task Force reaffirmed           “cascade” screening of other family members when a patient
its previous assessment that evidence is insufficient to assess          with familial hypercholesterolemia is identified.1
the balance of benefits and harms of screening for lipid dis-               A reasonable practice is to combine the NICE and Amer-
orders in children and adolescents younger than 20 years.5               ican Heart Association approaches and order a lipid profile
The recommendation acknowledges the lack of evidence that                for all family members older than 9 years who have a first-
screening improves long-term health outcomes;​however, the               degree relative with a premature ASCVD event or a relative
decision not to screen may lead to missed opportunities for              receiving treatment for LDL cholesterol greater than 190
early diagnosis and preventive treatment that can reduce the             mg per dL. The Dutch Criteria for Familial Hypercholes-
morbidity and mortality from ASCVD events that can occur                 terolemia is a validated tool to assist clinicians in screening
before 50 years of age.6                                                 decisions and diagnosis (https://​w ww.mdcalc.com/calc/3818/
   The U.S. Preventive Services Task Force states, “…clinicians          dutch-criteria-familial-hypercholesterolemia-fh).
are encouraged to use their judgment when deciding whether to               After patients with familial hypercholesterolemia are iden-
screen for lipid disorders in children and adolescents.”5 What,          tified, family physicians should provide lifestyle guidance to
then, is a pragmatic approach to balance the opportunity for             optimize blood pressure, weight, diet, physical activity, and
early diagnosis with the possible harms of treatment?                    tobacco cessation. Unless the physician has expertise with phar-
   The National Heart, Lung, and Blood Institute and Ameri-              macologic management of children and adults with familial
can Academy of Pediatrics recommend universal screening for              hypercholesterolemia, referral to a cardiologist or lipidologist
children 9 to 11 years of age as one approach.6 Most clinicians          specializing in prevention is prudent.
                                                                            Several medications that markedly reduce LDL cholesterol are
                                                                         often combined. These include proprotein convertase subtilisin/
                                                                         kexin type 9 (PCSK9) inhibitors (e.g., inclisiran [available as
   BRIAN V. REAMY, MD, FAAFP, Uniformed Services Uni-
                                                                         brand name Leqvio], PCSK9 siRNA), microsomal triglycer-
   versity of the Health Sciences, Bethesda, Maryland
                                                                         ide transfer protein inhibitors (lomitapide [available as brand
   Author disclosure:​No relevant financial relationships.               name Juxtapid]), and angiopoietin-like protein 3 inhibitors
   Address correspondence to Brian V. Reamy, MD, FAAFP,                  [evinacumab [available as brand name Evkeeza]). Other agents in
   at Brian.reamy@​usuhs.edu.                                            phase 3 trials (e.g., pelacarsen, PSCK9 vaccines, olezarsen) may
                                                                         soon be used in familial hypercholesterolemia management.10

              Downloaded from the American Family Physician website at www.aafp.org/afp. Copyright © 2024 American Acad-
226 American Family Physician	                                                                         Volume 110, Number 3 • September 2024
               emy of Family Physicians. For the private, noncommercial use of one individual user of the website. All other rights
                           reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                                                                                                     EDITORIALS


   Family physicians have an opportunity to identify and care             3. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with
for patients at high risk of ASCVD due to heterozygous famil-                familial hypercholesterolemia. Cochrane Database Syst Rev. 2019;​(11):​
                                                                             CD006401.
ial hypercholesterolemia before the onset of cardiovascular
                                                                          4. de Ferranti SD, Moran AE, Kazi DS. Still “on the fence” about universal
clinical events. The proven benefit of LDL cholesterol reduc-                childhood lipid screening. JAMA. 2023;​330(3):​225-227.
tion in the primary prevention of cardiovascular morbidity                5. U.S. Preventive Services Task Force. Lipid disorders in children and
and mortality in high-risk patients supports identification and              adolescents:​screening. July 18, 2023. Accessed July 30, 2024. https://​
treatment of all patients with familial hypercholesterolemia.11              www.uspreventive​services​t ask​force.org/home/getfilebytoken/
                                                                             vmHooQ6ABG9CagdUXv2_rx
Customizing and incorporating the NICE and American
                                                                          6. National Heart, Lung, and Blood Institute. Expert Panel on Integrated
Heart Association recommended approaches, as well as using
                                                                             Guidelines for Cardiovascular Health and Risk Reduction in Children
the Dutch criteria, can identify patients with familial hyper-               and Adolescents. Pediatrics. 2011;​128(suppl 5):​S213-S256.
cholesterolemia so that potentially life-saving preventive                 7. de Ferranti SD, Rodday AM, Parsons SK, et al. Cholesterol screening
interventions can be initiated.                                               and treatment practices and preferences:​a survey of United States
                                                                              pediatricians. J Pediatr. 2017;​185:​99.e2-105.e2.
This editorial represents the views of the author and does not            8. National Institute for Health Care and Excellence. Familial
represent the views of the Uniformed Services University of the              hypercholesterolaemia:​identification and management. Updated
Health Sciences or the U.S. Department of Defense.                           October 4, 2019. Accessed July 30, 2024. https://​w ww.nice.org.uk/
                                                                             guidance/cg71/chapter/recommendations
                                                                           9. McErlean S, Mbakaya B, Kennedy C. Familial hypercholesterolaemia
REFERENCES                                                                    [published correction appears in BMJ. 2023;​382:​194 5]. BMJ. 2023:​
1. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, et al. Diagnosis            382:​e 073280.
   and treatment of heterozygous familial hypercholesterolemia. J Am
                                                                          10. Reamy BV, Ford B, Goodman C. Novel pharmacotherapies for
   Heart Assoc. 2019;​8(24):​e 013225.
                                                                              hyperlipidemia. Prim Care. 2024 ;​51(1):​27-4 0.
2. Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of familial
                                                                          11. Mangione CM, Barry MJ, Nicholson WK, et al. Statin use for the
   hypercholesterolemia among the general population and patients
                                                                              primary prevention of cardiovascular disease in adults:​US Preventive
   with atherosclerotic cardiovascular disease:​a systematic review and
                                                                              Services Task Force recommendation statement. JAMA. 2022;​328(8):​
   meta-analysis. Circulation. 2020;​141(22):​1742-1759.
                                                                              74 6-753. ■




                                                                                              68% of smokers
                                                                                        say they want to quit.
                                                                                       Only about 7% succeed.
                                                                                             Ask your patients if they use
                                                                                          tobacco, and if they’re ready to
                                                                                            consider quitting. If they are,
                                                                                           Tobacco Free Florida can help.
                                                                                        Your referral, even a brief one,
                                                                                          can make all the difference.




    For more information on how you can team up with us to help
    your 2024
September patients   quit,
              • Volume       visit tobaccofreeflorida.com/healthcare.
                       110, Number  3                                                                            American Family Physician 227
